UBS
http://www.ubs.com/UBS provides a range of financial services, including advisory services, underwriting, financing, market making, asset management, brokerage and retail banking on a global level. The Company consists of four divisions: Wealth Management, Asset Management, Investment Banking & Security and Swiss Retail & Corporate Banking. Wealth Management offers high net worth customers advice and investment services, Asset Management offers management solutions for most types of asset class to a range of clients, Investment Banking & Security provides securities, products and research in various areas equities and Swiss Retail & Corporate Banking offers banking and securities services for Swiss clients.
-
-
-
-
-
-
-
Celgene (CELG) Reports Investigational Data Evaluating ABRAXANE Regimen for Patients with Locally Advanced Pancreatic Cancer
-
-
-
-
-
-
-
Celgene (CELG) Says Investigational Studies in Solid Tumor and Blood Cancers to Be Presented at ASCO
-
-
-
-
-
-
-
Notable 52-Week Highs and Lows of the Day 8/26: (ACHN) (AVNR) (CELG) High; (XUE) (AMPE) Low
-
-
-
-
-
-
-
UBS Upgrades Celgene (CELG) to Buy
-
-
-
-
-
-
-
UBS Suggest Buying Celgene (CELG) on Pullback; Key Takeaways From Conference Call
-
-
-
-
-
-
-
UBS Initiates Coverage on Celgene (CELG) with a Buy; Estimates Still Too Conservative
-
-
-
-
-
-
-
Notable Analyst Rating Changes 9/2: TXT, CBE, SI, PAY, BBD Upgraded; ROK, GIS, HOLX, DHI, RYL, NVAX Downgraded
-
126,077 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All